Dr. Sourav Santra

Sarepta Therapeutics, USA

Associate Professor

Email: [email protected]

Qualifications

2007 Ph.D., Northern Illinois University, USA

2000 M.Sc., Calcutta University, India

1998 B.Sc., Calcutta University, India

Publications (Selected)

1. Tian, C., Grabich, S., Veerapandiyan, A., et al. (2026). Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD. Journal of Comparative Effectiveness Research, 15(5). Advance online publication.
2. Adak, A., Santra, S., Ghosh, K., et al. (2026). Bioenrichment of vanillic acid and quercetin-3-O-glucuronide prevailed phenolics in a rice fermented beverage with potential antioxidant activity via induction of Nrf2 signalling pathway. Journal of Food Science and Technology-Mysore. Advance online publication.
3. Raj, Aditya, Chakravorty, Arghya, Luktuke, Sahil, et al. (2025). Anti-Inflammatory Potential of Costus speciosus rhizome Bioactive Phytochemicals: A Combined GC-MS and Computational Approach Targeting TLR-4 Signaling. Current Computer-Aided Drug Design, 21(3), 285–301.
4. Grabich, S., Santra, S., Waldrop, M., et al. (2023). Interim analysis of EVOLVE: evaluating Eteplirsen, Golodirsen, or Casimersen treatment in patients <7 years old in routine clinical practice. Neuromuscular Disorders, 33(Suppl 1), S104–S105.
5. Grabich, S., Ricchetti-Masterson, K., Santra, S., et al. (2023). Improving longitudinally in rare disease data capture in real-world evidence combining clinical trials and observational data: A case study using EVOLVE. Pharmacoepidemiology and Drug Safety, 32(Suppl 1), 547–547.
6. Mondal, S., Rakshit, S., Pal, K., et al. (2023). Production of glutathione from probiotic Bacillus amyloliquefaciens KMH10 using banana peel extract. Bioresource Technology, 376, Article 128910.
7. Das, S., Dey, A., Maji, S., et al. (2023). Attenuation of fluoride-induced hepatorenal oxidative stress by ferulic acid in vivo: An approach with in-silico analysis and interaction informatics of ferulic acid. Journal of Trace Elements in Medicine and Biology, 77, Article 127133.
8. Goedeker, N. L. L., Dharia, S. D. D., Griffin, D. A. A., et al. (2023). Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Therapeutic Advances in Neurological Disorders, 16, Article 17562864221149781.
9. Ricchetti-Masterson, K., Santra, S., Hornibrook, S., et al. (2022). Interim analysis of EVOLVE: a long-term observational study evaluating eteplirsen, golodirsen, or casimersen in routine clinical practice. Neuromuscular Disorders, 32(Suppl 1).
10. Mondal, S., Santra, S., Uddin, H., et al. (2022). Application of Phytochemicals To Combat Fungal Pathogens of Pulses: An Approach toward Inhibition of Fungal Propagation and Invasin Activity. Journal of Agricultural and Food Chemistry, 70(25), 7662–7673.
11. Hor, P. K., Pal, S., Mondal, J., et al. (2022). Antiobesity, Antihyperglycemic, and Antidepressive Potentiality of Rice Fermented Food Through Modulation of Intestinal Microbiota. Frontiers in Microbiology, 13, Article 794503.
12. Goedeker, N. L., Griffin, D., Dharia, S., et al. (2022). Evaluation of Total Binding Antibodies Against rAAVrh74 in Patients with Duchenne Muscular Dystrophy. Molecular Therapy, 30(4, Supp 1), 563–563.
13. Mitelman, O., Abdel-Hamid, H. Z., Byrne, B. J., et al. (2022). A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Journal of Neuromuscular Diseases, 9(1), 39–52.
14. Mondal, S., Santra, S., Rakshit, S., et al. (2022). Saccharification of lignocellulosic biomass using an enzymatic cocktail of fungal origin and successive production of butanol by Clostridium acetobutylicum. Bioresource Technology, 343, Article 126093.
15. Butzkueven, H., Licata, S., Jeffery, D., et al. (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open, 10(10), Article e038861.
16. Perumal, J., Fox, R. J., Balabanov, R., et al. (2019). Outcomes of natalizumab treatment within 3years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurology, 19, Article 116.
17. Gudesblatt, M., Wissemann, K., Zarif, M., et al. (2018). Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis. CNS Drugs, 32(12), 1173–1181.
18. Gudesblatt, M., Wissemann, K., Zarif, M., et al. (2018). Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis (vol 32, pg 1173, 2018). CNS Drugs, 32(12), 1183–1183.
19. Gudesblatt, M., Srinivasan, J., LaBozzetta, C., et al. (2018). Evaluation of changes in cognitive function as assessed by NeuroTrax in patients with multiple sclerosis treated with natalizumab for up to 5 years. Multiple Sclerosis Journal, 24(Suppl 2), 800–801.
20. Perumal, J., Fox, R. J., Balabanov, R., et al. (2018). Natalizumab is associated with no evidence of disease activity and improved cognitive function and health-related quality of life in anti-JC virus seronegative patients with early relapsing-remitting multiple sclerosis: a 3-year analysis of STRIVE. Multiple Sclerosis Journal, 24(Suppl 2), 477–478.

Profile Details
https://scholar.google.com/citations?user=fpJx0RwAAAAJ&hl=en
https://www.researchgate.net/profile/Sourav-Santra

WOS ResearcherID: PXT-6175-2026